CONTINGENT LIABILITIES AND COMMITMENTS (Details Narrative) |
9 Months Ended |
|---|---|
|
Apr. 30, 2026
USD ($)
shares
| |
| Office and Lab Space [Member] | |
| Loss Contingencies [Line Items] | |
| Operating lease payments | $ | $ 43,500 |
| Amalgamation Agreement [Member] | |
| Loss Contingencies [Line Items] | |
| Warrants exercisable | 27,984 |
| Amalgamation Agreement [Member] | Bria Cell Therapeutics [Member] | |
| Loss Contingencies [Line Items] | |
| Warrants shares | 27,984 |
| Amalgamation Agreement [Member] | BriaPro Therapeutics Corp, [Member] | |
| Loss Contingencies [Line Items] | |
| Warrants shares | 4,197,831 |
| Maximum [Member] | Amalgamation Agreement [Member] | |
| Loss Contingencies [Line Items] | |
| Warrants amount | $ | $ 133,320 |
| X | ||||||||||
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Number of warrants or rights outstanding. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|